

- Bergmann AK, Castellano G, Alten J, Ammerpohl O, Kolarova J, Nordlund J, Martin-Subero JI, Schrappe M, Siebert R. DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites. *Pediatr Blood Cancer*. doi: 10.1002/pbc.26251 (2016).
- Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, Spielberg S, Vossen-Gajcy M, Cario G, Schrappe M, Schewe DM. The role of Zeta-chain-associated protein kinase in acute lymphoblastic leukemia infiltration into the central nervous system. *Haematologica* pii: haematol.2016.147744 (2016).
- Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S, Askmyr M, Rissler M, Schrappe M, Cario G, Castor A, Pronk CJ, Behrendtz M, Mitelman F, Johansson B, Paulsson K, Andersson AK, Fontes M, Fioretos T. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. *Nat Commun* **7**, 11790 (2016).
- Hobeika E, Levit-Zerdoun E, Anastasopoulou V, Pohlmeier R, Altmeier S, Alsadeq A, Dobenecker MW, Pelanda R, Reth M. CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk. *EMBO J* **34(7)**, 925-939 (2015).
- Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva Filho MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. *Sci Rep* **5**, 15065-15065 (2015).
- Kretzmer H, Bernhart SH, Wang W, Haake A, Weniger MA, Bergmann AK, Betts MJ, Carrillo-de-Santa-Pau E, Doose G, Gutwein J, Richter J, Hovestadt V, Huang B, Rico D, Jühling F, Kolarova J, Lu Q, Otto C, Wagener R, Arnolds J, Burkhardt B, Claviez A, Drexler HG, Eberth S, Eils R, Flicek P, Haas S, Hummel M, Karsch D, Kerstens HH, Klapper W, Kreuz M, Lawerenz C, Lenze D, Loeffler M, López C, MacLeod RA, Martens JH, Kulis M, Martín-Subero JI, Möller P, Nagel I, Picelli S, Vater I, Rohde M, Rosenstiel P, Rosolowski M, Russell RB, Schilhabel M, Schlesner M, Stadler PF, Szczepanowski M, Trümper L, Stunnenberg HG; ICGC MMML-Seq project; BLUEPRINT project, Küppers R, Ammerpohl O, Lichter P, Siebert R, Hoffmann S, Radlwimmer B. DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. *Nat Genet* **47(11)**, 1316-1325 (2015).
- Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, Bornhauser B, Gombert M, Kratsch C, Stütz AM, Sultan M, Tchinda J, Worth CL, Amstislavskiy V, Badarinarayan N, Baruchel A, Bartram T, Basso G, Canpolat C, Cario G, Cavé H, Dakaj D, Delorenzi M, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas OA, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Höll JI, Hornhardt S, Husemann P, Kachroo P, Kratz CP, Kronnie GT, Marovca B, Niggli F, McHardy AC, Moorman AV, Panzer-Grümayer R, Petersen BS, Raeder B, Ralser M,

Rosenstiel P, Schäfer D, Schrappe M, Schreiber S, Schütte M, Stade B, Thiele R, Weid Nv, Vora A, Zaliouva M, Zhang L, Zichner T, Zimmermann M, Lehrach H, Borkhardt A, Bourquin JP, Franke A, Korbel JO, Stanulla M, Yaspo ML. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. *Nat Genet* **47(9)**, 1020-1029 (2015).

- Zaliouva M, Zimmermannova O, Dörge P, Eckert C, Möricke A, Zimmermann M, Stuchly J, Teigler-Schlegel A, Meissner B, Koehler R, Bartram CR, Karawajew L, Rhein P, Zuna J, Schrappe M, Cario G, Stanulla M. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. *Leukemia* **29(3)**, 1038–1038 (2015).
- Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. *Leukemia* **29(3)**, 696–704 (2015).
- Malinowska-Ozdowy K, Frech C, Schönegger A, Eckert C, Cazzaniga G, Stanulla M, zur Stadt U, Mecklenbräuker A, Schuster M, Kneidinger D, von Stackelberg A, Locatelli F, Schrappe M, Horstmann MA, Attarbaschi A, Bock C, Mann G, Haas OA, Panzer-Grümayer R. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. *Leukemia* **29(8)**, 1656–1667 (2015).
- Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso JA, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe DM. Effects of p38 $\alpha$ / $\beta$  inhibition on acute lymphoblastic leukemia proliferation and survival in vivo. *Leukemia* **29(12)**, 2307–2316 (2015).
- Kunz JB, Rausch T, Bandapalli OR, Eilers J, Pechanska P, Schuessle S, Assenov Y, Stütz AM, Kirschner-Schwabe R, Hof J, Eckert C, von Stackelberg A, Schrappe M, Stanulla M, Koehler R, Avigad S, Elitzur S, Handgretinger R, Benes V, Weischenfeldt J, Korbel JO, Muckenthaler MU, Kulozik AE. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. *Haematologica* **100(11)**, 1442-1450 (2015).
- Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-Ghiso JA. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. *BMC Cancer* **15**, 1460-1461 (2015).
- Oevermann L, Firnkorn M, Michaelis S, Müller S, Schaeffeler E, Schrappe M, Cario G, Stanulla M, Schwab M, Handgretinger R, Mezger M. No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. *Blood* **125(21)**, 3355-3357 (2015).
- Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe DM. Mer tyrosine kinase promotes the survival of t(1;19)-positive

acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). *Blood* **125(5)**, 820-830 (2015).

- Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe DM, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S. Central nervous system acute lymphoblastic leukemia: role of natural killer cells. *Blood* **125(22)**, 3420-3431 (2015).
- Bouter J, Huang Y, Marovca B, Vonderheit A, Grotzer MA, Eckert C, Cario G, Wollscheid B, Horvath P, Bornhauser BC, Bourquin JP. Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. *Oncotarget* **5(22)**, 11501-11512 (2014).
- Zaliouva M, Zimmermannova O, Dörge P, Eckert C, Möricke A, Zimmermann M, Stuchly J, Teigler-Schlegel A, Meissner B, Koehler R, Bartram CR, Karawajew L, Rhein P, Zuna J, Schrappe M, Cario G, Stanulla M. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. *Leukemia* **28(1)**, 182–185 (2014).
- Slamova L, Starkova J, Fronkova E, Zaliouva M, Reznickova L, van Delft FW, Vodickova E, Volejnikova J, Zemanova Z, Polgarova K, Cario G, Figueroa M, Kalina T, Fiser K, Bourquin JP, Bornhauser B, Dworzak M, Zuna J, Trka J, Sary J, Hrusak O, Mejstrikova E. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. *Leukemia* **28(3)**, 609–620 (2014).
- Meissner B, Bartram T, Eckert C, Trka J, Panzer-Grümayer R, Hermanova I, Ellinghaus E, Franke A, Möricke A, Schrauder A, Teigler-Schlegel A, Dörge P, von Stackelberg A, Basso G, Bartram CR, Kirschner-Schwabe R, Bornhäuser B, Bourquin JP, Cazzaniga G, Hauer J, Attarbaschi A, Izraeli S, Zaliouva M, Cario G, Zimmermann M, Avigad S, Sokalska-Duhme M, Metzler M, Schrappe M, Koehler R, Te Kronnie G, Stanulla M. Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. *Hum Mol Genet* **23(3)**, 590–601 (2014).
- Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* **99(1)**, 103-110 (2014).
- Bandapalli OR, Schuessle S, Kunz JB, Rausch T, Stütz AM, Tal N, Geron I, Gershman N, Izraeli S, Eilers J, Vaezipour N, Kirschner-Schwabe R, Hof J, von Stackelberg A, Schrappe M, Stanulla M, Zimmermann M, Koehler R, Avigad S, Handgretinger R, Frismantas V, Bourquin JP, Bornhauser B, Korbel JO, Muckenthaler MU, Kulozik AE. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. *Haematologica* **99(10)**, 188-192 (2014).
- Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR, Zimmermann M, Damm-Welk C, Russell RB, Borkhardt A, Eils R, Hoell JI,

Szczepanowski M, Oschlies I, Klapper W, Burkhardt B, Siebert R; German ICGC MML-Seq-Project; NHL-BFM Study Group. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. *Genes Chromosomes Cancer* **53(11)**, 911–916 (2014).

- Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga Penas E, Vater I, Jayne S, Dyer MJ, Schrappe M, Dührsen U, Ammerpohl O, Russell RB, Küppers R, Dürig J, Siebert R. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. *Genes Chromosomes Cancer* **53(4)**, 309–316 (2014).
- van der Veer A, Zaliouva M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, Pieters R, Biondi A, Valsecchi MG, Stanulla M, den Boer ML, Cazzaniga G. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. *Blood* **123(11)**, 1691-1698 (2014).
- Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Küppers R, Lefebvre C, Lisfeld J, Löffler M, Macleod RA, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trümper L, Vater I, Wessendorf S, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphoma Network Project; Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. *Blood* **123(8)**, 1187-1198 (2014).
- Lustfeld I, Altvater B, Ahlmann M, Ligges S, Brinkrolf P, Rosemann A, Moericke A, Rossig C. High proportions of CD4<sup>+</sup> T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses. *Acta Haematol* **131(1)**, 28-36 (2014).
- Volejnikova J, Mejstrikova E, Dörge P, Meissner B, Zimmermannova O, Svojgr K, Stanulla M, Cario G, Schrappe M, Stary J, Hrusak O, Trka J, Fronkova E. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia. *Pediatr Blood Cancer* **60(3)**, 420-427 (2013).
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichten P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. *Nature* **500(746)**, 415-421 (2013).

- Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM, Aguirre-Ghiso JA. TGF- $\beta$ 2 dictates disseminated tumour cell fate in target organs through TGF- $\beta$ -RIII and p38 $\alpha$ / $\beta$  signalling. *Nat Cell Biol* **15(11)**, 1351–1361 (2013).
- Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R. The MLL recombinome of acute leukemias in 2013. *Leukemia* **27(11)**, 2165–2176 (2013).
- Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, Peipp M. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. *Leukemia* **27(7)**, 1595–1598 (2013).
- Harder L, Eschenburg G, Zech A, Kriebitzsch N, Otto B, Streichert T, Behlich AS, Dierck K, Klingler B, Hansen A, Stanulla M, Zimmermann M, Kremmer E, Stocking C, Horstmann MA. Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia. *J Exp Med* **210(11)**, 2289–2304 (2013).
- Woiterski J, Ebinger M, Witte KE, Goecke B, Heininger V, Philippek M, Bonin M, Schrauder A, Röttgers S, Herr W, Lang P, Handgretinger R, Hartwig UF, André MC. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2R $\gamma$  null mice reflects individual leukemogenicity and highly correlates with clinical outcome. *Int J Cancer* **133(7)**, 1547-1556 (2013).
- Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel A, Ratei R, Ludwig WD, Koehler R, Bartram CR, Schrappe M, Stanulla M, Cario G. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* **98(3)**, 428-432 (2013).
- Schrappe M, Ludwig WD, Koehler R, Muckenthaler MU, Kulozik AE. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. *Haematologica* **98(6)**, 928-936 (2013).

- Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. *Embo Mol Med* **5(1)**, 38-51 (2013).
- Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. *Blood* **121(26)**, 5145-5153 (2013).
- Mirkowska P, Hofmann A, Sedek L, Slamova L, Mejstrikova E, Szczepanski T, Schmitz M, Cario G, Stanulla M, Schrappe M, van der Velden VH, Bornhauser BC, Wollscheid B, Bourquin JP. Leukemia surfaceome analysis reveals new disease-associated features. *Blood* **121(25)**, 149-159 (2013).
- Migliorini G, Fiege B, Hosking FJ, Ma Y, Kumar R, Sherborne AL, da Silva Filho MI, Vijayakrishnan J, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson P, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Zimmermann M, Bartram CR, Schrappe M, Greaves M, Stanulla M, Hemminki K, Houlston RS. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. *Blood* **122(19)**, 3298-3307 (2013).
- Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. *Blood* **122(14)**, 2443-2452 (2013).
- Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischmarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; ICGC MMML-Seq Project. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet* **44(12)**, 1316-1320 (2012).
- Denk D, Nebral K, Bradtke J, Pass G, Möricke A, Attarbaschi A, Strehl S. PAX5-AUTS2: a recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia. *Leukemia Res* **36(8)**, 178-181 (2012).
- Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, Shochat C, Stanulla M, Rossi V, Di Meglio AM, Villa T, Giarin E, Fazio G, Leszl A, Schrappe M, Basso G, Biondi A, Izraeli S, Conter V, Valsecchi MG, Cazzaniga G, Te Kronnie G. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. *Leukemia* **26(10)**, 2245-2253 (2012).

- Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, Karawajew L, Maglia O, Ratei R, Benetello A, Sala S, Schumich A, Schrauder A, Villa T, Veltroni M, Ludwig WD, Conter V, Schrappe M, Biondi A, Dworzak MN, Basso G. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. *Haematologica* **97(10)**, 1582-1593 (2012).
- Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Pötschger U, Harrison CJ, Stanulla M, Panzer-Grümayer R, Haas OA, Moorman AV; Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Berlin-Frankfurt-Münster (BFM) Study Group and National Cancer Research Institute (NCRI)-Children's Cancer and Leukaemia (CCLG) Study Group. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. *Br J Haematol*. **158(6)**, 772-777 (2012).
- Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S, Krentz S, Cario G, Kasper D, Schmitt K, Russell LJ, Pötschger U, Stanulla M, Eckert C, Mann G, Haas OA, Panzer-Grümayer R. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. *Blood* **120(26)**, 5134-5142 (2012).
- Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. *Blood* **119(9)**, 1963-1971 (2012).
- Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthous T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. *Blood* **120(2)**, 395-403 (2012).
- Herrmann J, Junge CM, Burdelski M, Ganschow R, Scheibner S, Petersen KU, Fischer L, Broering DC, Adam G, Helmke K. Transcapsular arterial neovascularization after liver transplantation in pediatric patients indicates transplant failure. *Radiology* **261(2)**, 566-572 (2011).
- Zaliouva M, Meyer C, Cario G, Vaskova M, Marschalek R, Stary J, Zuna J, Trka J. TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases. *Pediatr Blood Cancer* **56(2)**, 217-225 (2011).
- Takeuchi S, Matsushita M, Zimmermann M, Ikezoe T, Komatsu N, Seriu T, Schrappe M, Bartram CR, Koeffler HP. Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. *Leukemia Res* **35(10)**, 1345-1349 (2011).

- Zaliova M, Madzo J, Cario G, Trka J. Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing. *Leukemia* **25(2)**, 313–320 (2011).
- Ellinghaus E, Stanulla M, Richter G, Ellinghaus D, Te Kronnie G, Cario G, Cazzaniga G, Horstmann M, Panzer Grümayer R, Cavé H, Trka J, Cinek O, Teigler-Schlegel A, Elsharawy A, Häsler R, Nebel A, Meissner B, Bartram T, Lescai F, Franceschi C, Giordan M, Nürnberg P, Heinzow B, Zimmermann M, Schreiber S, Schrappe M, Franke A. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. *Leukemia* **26(5)**, 902-9 (2012).
- Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, Cario G, Cazzaniga G, Kulozik AE, Stanulla M, Schrappe M, Biondi A, Basso G, Bercovich D, Muckenthaler MU, Izraeli S. Gain-of-function mutations in interleukin-7 receptor-? (IL7R) in childhood acute lymphoblastic leukemias. *J Exp Med* **208(5)**, 901–908 (2011).
- Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, Stadt UZ, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JP, van Dongen JJ. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. *J Clin Oncol* **29(12)**, 1643-1649 (2011).
- Sherborne AL, Hemminki K, Kumar R, Bartram CR, Stanulla M, Schrappe M, Petridou E, Semsei AF, Szalai C, Sinnott D, Krajcinovic M, Healy J, Lanciotti M, Dufour C, Indaco S, El-Ghouroury EA, Sawangpanich R, Hongeng S, Pakakasama S, Gonzalez-Neira A, Ugarte EL, Leal VP, Espinoza JP, Kamel AM, Ebid GT, Radwan ER, Yalin S, Yalin E, Berkov M, Simpson J, Roman E, Lightfoot T, Hosking FJ, Vijayakrishnan J, Greaves M, Houlston RS. Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. *Haematologica* **96(7)**, 1049-1054 (2011).
- Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, Zangrando A, Vendramini E, Möricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler HA, Te Kronnie G, Debatin KM. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. *Cancer Cell* **19(2)**, 206-217 (2011).
- Back C, Knauss H, Ludwig WD, Schrappe M, Debatin KM, Beltinger C. Mitochondrial genome variants in non-remitting ALL of childhood. *Br. J. Haematol* **155(5)**, 626-629 (2011).
- Kreyenberg H, Jarisch A, Bayer C, Schuster B, Willasch A, Strahm B, Kremens B, Gruhn B, Schrauder A, Burdach S, Führer M, Rossig C, Kabisch H, Schlegel PG, Stachel D, Beck JF, Mauz-Koerholz C, Chung TL, Holler E, Klingebiel T, Bader P. NOD2/CARD15 gene polymorphisms affect outcome in pediatric allogeneic stem cell transplantation. *Blood* **118(4)**, 1181-1184 (2011).
- Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D. Second induction with high-dose cytarabine and mitoxantrone: different



impact on pediatric AML patients with t(8;21) and with inv(16). *Blood* **118**(20), 5409-5415 (2011).

- Shochat, C., Tal, N., Bandapalli, O.R., Palmi, C., Ganmore, I., te Kronnie, G., Cario, G., Cazzaniga, G., Kulozik, A.E., Stanulla, M., Schrappe, M., Biondi, A., Basso, G., Bercovich, D., Muckenthaler, M.U. & Izraeli, S. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. *J Exp Med* **208**, 901-908 (2011).
- Schrey, D., Speitel, K., Lanvers-Kaminsky, C., Gerss, J., Moricke, A. & Boos, J. Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial. *Pediatr Blood Cancer* **57**, 378-384 (2011).
- Schmitz, M., Breithaupt, P., Scheidegger, N., Cario, G., Bonapace, L., Meissner, B., Mirkowska, P., Tchinda, J., Niggli, F.K., Stanulla, M., Schrappe, M., Schrauder, A., Bornhauser, B.C. & Bourquin, J.P. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. *Blood* **118**, 1854-1864 (2011).
- Meyer, L.H., Eckhoff, S.M., Queudeville, M., Kraus, J.M., Giordan, M., Stursberg, J., Zangrando, A., Vendramini, E., Moricke, A., Zimmermann, M., Schrauder, A., Lahr, G., Holzmann, K., Schrappe, M., Basso, G., Stahnke, K., Kestler, H.A., Te Kronnie, G. & Debatin, K.M. Early relapse in all is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. *Cancer Cell* **19**, 206-217 (2011).
- Sherborne, A.L., Hosking, F.J., Prasad, R.B., Kumar, R., Koehler, R., Vijayakrishnan, J., Papaemmanuil, E., Bartram, C.R., Stanulla, M., Schrappe, M., Gast, A., Dobbins, S.E., Ma, Y., Sheridan, E., Taylor, M., Kinsey, S.E., Lightfoot, T., Roman, E., Irving, J.A., Allan, J.M., Moorman, A.V., Harrison, C.J., Tomlinson, I.P., Richards, S., Zimmermann, M., Szalai, C., Semsei, A.F., Erdelyi, D.J., Krajcinovic, M., Sinnett, D., Healy, J., Gonzalez Neira, A., Kawamata, N., Ogawa, S., Koeffler, H.P., Hemminki, K., Greaves, M. & Houlston, R.S. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. *Nat Genet* **42**, 492-494 (2010).
- Schrey, D., Borghorst, S., Lanvers-Kaminsky, C., Hempel, G., Gerss, J., Moricke, A., Schrappe, M. & Boos, J. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. *Pediatr Blood Cancer* **54**, 952-958 (2010).
- Rhein, P., Mitlohner, R., Basso, G., Gaipa, G., Dworzak, M.N., Kirschner-Schwabe, R., Hagemeyer, C., Stanulla, M., Schrappe, M., Ludwig, W.D., Karawajew, L. & Ratei, R. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. *Blood* **115**, 3763-3771 (2010).
- Kox, C., Zimmermann, M., Stanulla, M., Leible, S., Schrappe, M., Ludwig, W.D., Koehler, R., Tolle, G., Bandapalli, O.R., Breit, S., Muckenthaler, M.U. & Kulozik, A.E. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. *Leukemia* **24**, 2005-2013 (2010).
- Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., Cario, G.,

Stanulla, M., Strehl, S., Russell, L.J., Harrison, C.J., Bornhauser, B., Yoda, A., Rechavi, G., Bercovich, D., Borkhardt, A., Kempfski, H., te Kronnie, G., Bourquin, J.P., Domany, E. & Izraeli, S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood* **115**, 1006-1017 (2010).

- Harrison, C.J., Haas, O., Harbott, J., Biondi, A., Stanulla, M., Trka, J. & Izraeli, S. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. *Br J Haematol* **151**, 132-142 (2010).
- Dworzak, M.N., Gaipa, G., Schumich, A., Maglia, O., Ratei, R., Veltroni, M., Husak, Z., Basso, G., Karawajew, L., Gadner, H. & Biondi, A. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. *Cytometry B Clin Cytom* **78**, 147-153 (2010).
- Bruggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O.G., Asnafi, V., Baruchel, A., Bassan, R., Benoit, Y., Biondi, A., Cave, H., Dombret, H., Fielding, A.K., Foa, R., Gokbuget, N., Goldstone, A.H., Goulden, N., Henze, G., Hoelzer, D., Janka-Schaub, G.E., Macintyre, E.A., Pieters, R., Rambaldi, A., Ribera, J.M., Schmiegelow, K., Spinelli, O., Stary, J., von Stackelberg, A., Kneba, M., Schrappe, M. & van Dongen, J.J. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. *Leukemia* **24**, 521-535 (2010).
- Bonapace, L., Bornhauser, B.C., Schmitz, M., Cario, G., Ziegler, U., Niggli, F.K., Schafer, B.W., Schrappe, M., Stanulla, M. & Bourquin, J.P. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *J Clin Invest* **120**, 1310-1323 (2010).
- Schwarz, A.K., Stanulla, M., Cario, G., Flohr, T., Sutton, R., Moricke, A., Anker, P., Stroun, M., Welte, K., Bartram, C.R., Schrappe, M. & Schrauder, A. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. *Ann Hematol* **88**, 897-905 (2009).
- Remke, M., Pfister, S., Kox, C., Toedt, G., Becker, N., Benner, A., Werft, W., Breit, S., Liu, S., Engel, F., Wittmann, A., Zimmermann, M., Stanulla, M., Schrappe, M., Ludwig, W.D., Bartram, C.R., Radlwimmer, B., Muckenthaler, M.U., Lichter, P. & Kulozik, A.E. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. *Blood* **114**, 1053-1062 (2009).
- Ratei, R., Basso, G., Dworzak, M., Gaipa, G., Veltroni, M., Rhein, P., Biondi, A., Schrappe, M., Ludwig, W.D. & Karawajew, L. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive

impact of early blast reduction on the remission status after induction. *Leukemia* **23**, 528-534 (2009).

- Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., Delabesse, E., de Oliveira, M.P., Cave, H., Clappier, E., van Dongen, J.J., Balgobind, B.V., van den Heuvel-Eibrink, M.M., Beverloo, H.B., Panzer-Grumayer, R., Teigler-Schlegel, A., Harbott, J., Kjeldsen, E., Schnittger, S., Koehl, U., Gruhn, B., Heidenreich, O., Chan, L.C., Yip, S.F., Krzywinski, M., Eckert, C., Moricke, A., Schrappe, M., Alonso, C.N., Schafer, B.W., Krauter, J., Lee, D.A., Zur Stadt, U., Te Kronnie, G., Sutton, R., Izraeli, S., Trakhtenbrot, L., Lo Nigro, L., Tsaur, G., Fechina, L., Szczepanski, T., Strehl, S., Ilencikova, D., Molkentin, M., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. New insights to the MLL recombinome of acute leukemias. *Leukemia* **23**, 1490-1499 (2009).
- Lauten, M., Fernandez-Munoz, I., Gerdes, K., von Neuhoff, N., Welte, K., Schlegelberger, B., Schrappe, M. & Beger, C. Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. *Pediatr Blood Cancer* **52**, 459-463 (2009).
- Steinemann, D., Cario, G., Stanulla, M., Karawajew, L., Tauscher, M., Weigmann, A., Gohring, G., Ludwig, W.D., Harbott, J., Radlwimmer, B., Bartram, C., Lichter, P., Schrappe, M. & Schlegelberger, B. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. *Genes Chromosomes Cancer* **47**, 471-480 (2008).
- Kawamata, N., Ogawa, S., Zimmermann, M., Niebuhr, B., Stocking, C., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., Flohr, T., Miller, C.W., Harbott, J., Ludwig, W.D., Stanulla, M., Schrappe, M., Bartram, C.R. & Koefler, H.P. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. *Proc Natl Acad Sci USA* **105**, 11921-11926 (2008).
- Kawamata, N., Ogawa, S., Zimmermann, M., Kato, M., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., Flohr, T., Miller, C.W., Harbott, J., Ludwig, W.D., Stanulla, M., Schrappe, M., Bartram, C.R. & Koefler, H.P. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. *Blood* **111**, 776-784 (2008).
- Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grumayer, R., van der Velden, V., Fischer, S., Stanulla, M., Basso, G., Niggli, F.K., Schafer, B.W., Sutton, R., Koehler, R., Zimmermann, M., Valsecchi, M.G., Gadner, H., Masera, G., Schrappe, M., van Dongen, J.J., Biondi, A. & Bartram, C.R. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. *Leukemia* **22**, 771-782 (2008).
- Dworzak, M.N., Schumich, A., Printz, D., Potschger, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G. & Gadner, H. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during

induction treatment: setting the stage for anti-CD20 directed immunotherapy. *Blood* **112**, 3982-3988 (2008).

- Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O.A., Mann, G., Binder, V., Borkhardt, A., Kempfski, H., Trka, J., Biellorei, B., Avigad, S., Stark, B., Smith, O., Dastugue, N., Bourquin, J.P., Tal, N.B., Green, A.R. & Izraeli, S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet* **372**, 1484-1492 (2008).
- van der Velden, V.H., Panzer-Grumayer, E.R., Cazzaniga, G., Flohr, T., Sutton, R., Schrauder, A., Basso, G., Schrappe, M., Wijkhuijs, J.M., Konrad, M., Bartram, C.R., Masera, G., Biondi, A. & van Dongen, J.J. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. *Leukemia* **21**, 706-713 (2007).
- van der Velden, V.H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E. & van Dongen, J.J. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. *Leukemia* **21**, 604-611 (2007).
- Stanulla, M., Dynybil, C., Bartels, D.B., Dordelmann, M., Loning, L., Claviez, A. & Schrappe, M. The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. *Haematologica* **92**, 1581-1582 (2007).
- Rhein, P., Scheid, S., Ratei, R., Hagemeyer, C., Seeger, K., Kirschner-Schwabe, R., Moericke, A., Schrappe, M., Spang, R., Ludwig, W.D. & Karawajew, L. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. *Leukemia* **21**, 897-905 (2007).
- Gast, A., Bermejo, J.L., Flohr, T., Stanulla, M., Burwinkel, B., Schrappe, M., Bartram, C.R., Hemminki, K. & Kumar, R. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. *Leukemia* **21**, 320-325 (2007).
- Cario, G., Izraeli, S., Teichert, A., Rhein, P., Skokowa, J., Moricke, A., Zimmermann, M., Schrauder, A., Karawajew, L., Ludwig, W.D., Welte, K., Schunemann, H.J., Schlegelberger, B., Schrappe, M. & Stanulla, M. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. *J Clin Oncol* **25**, 4813-4820 (2007).
- Bornhauser, B.C., Bonapace, L., Lindholm, D., Martinez, R., Cario, G., Schrappe, M., Niggli, F.K., Schafer, B.W. & Bourquin, J.P. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. *Blood* **110**, 2084-2091 (2007).

- Meyer, L.H., Karawajew, L., Schrappe, M., Ludwig, W.D., Debatin, K.M. & Stahnke, K. Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. *Blood* **107**, 4524-4531 (2006).
- Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., Schoch, C., Jansen, M.W., van Dongen, J.J., den Boer, M.L., Pieters, R., Ennas, M.G., Angelucci, E., Koehl, U., Greil, J., Griesinger, F., Zur Stadt, U., Eckert, C., Szczepanski, T., Niggli, F.K., Schafer, B.W., Kempfski, H., Brady, H.J., Zuna, J., Trka, J., Nigro, L.L., Biondi, A., Delabesse, E., Macintyre, E., Stanulla, M., Schrappe, M., Haas, O.A., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. The MLL recombinome of acute leukemias. *Leukemia* **20**, 777-784 (2006).
- Metzler, M., Mann, G., Monschein, U., Lodzinski, M., Gall, C., Flohr, T., Viehmann, S., Langer, T., Schrappe, M., Gadner, H., Haas, O.A. & Panzer-Grumayer, E.R. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene. *Haematologica* **91**, 683-686 (2006).
- Maecker, B., Mougiakakos, D., Zimmermann, M., Behrens, M., Hollander, S., Schrauder, A., Schrappe, M., Welte, K. & Klein, C. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. *Leukemia* **20**, 645-649 (2006).
- Lauten, M., Schrauder, A., Kardinal, C., Harbott, J., Welte, K., Schlegelberger, B., Schrappe, M. & von Neuhoff, N. Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance. *Leukemia* **20**, 820-826 (2006).
- Kratz, C.P., Boll, S., Kontny, U., Schrappe, M., Niemeyer, C.M. & Stanulla, M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. *Leukemia* **20**, 381-383 (2006).
- Breit, S., Stanulla, M., Flohr, T., Schrappe, M., Ludwig, W.D., Tolle, G., Happich, M., Muckenthaler, M.U. & Kulozik, A.E. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. *Blood* **108**, 1151-1157 (2006).
- Schnakenberg, E., Mehles, A., Cario, G., Rehe, K., Seidemann, K., Schlegelberger, B., Elsner, H.A., Welte, K.H., Schrappe, M. & Stanulla, M. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. *BMC Med Genet* **6**, 23 (2005).
- Hotfilder, M., Rottgers, S., Rosemann, A., Schrauder, A., Schrappe, M., Pieters, R., Jurgens, H., Harbott, J. & Vormoor, J. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. *Cancer Res* **65**, 1442-1449 (2005).
- Metzler, M., Strissel, P.L., Strick, R., Niemeyer, C., Roettgers, S., Borkhardt, A., Harbott, J., Ludwig, W.D., Stanulla, M., Schrappe, M., Reinhardt, D., Creutzig, U., Beck, J.D., Rascher, W., Repp, R. & Langer, T. Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. *Genes Chromosomes Cancer* **41**, 291-296 (2004).

- Metzler, M., Brehm, U., Langer, T., Viehmann, S., Borkhardt, A., Stanulla, M., Schrappe, M., Harbott, J., Beck, J.D., Rascher, W. & Repp, R. Asymmetric multiplex-polymerase chain reaction - a high throughput method for detection and sequencing genomic fusion sites in t(4;11). *Br J Haematol* **124**, 47-54 (2004).
- Meissner, B., Stanulla, M., Ludwig, W.D., Harbott, J., Moricke, A., Welte, K. & Schrappe, M. The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. *Leukemia* **18**, 1920-1923 (2004).
- Kracht, T., Schrappe, M., Strehl, S., Reiter, A., Elsner, H.A., Trka, J., Cario, G., Viehmann, S., Harbott, J., Borkhardt, A., Metzler, M., Langer, T., Repp, R., Marschalek, R., Welte, K., Haas, O.A. & Stanulla, M. NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. *Haematologica* **89**, 1492-1497 (2004).
- Hubner, S., Cazzaniga, G., Flohr, T., van der Velden, V.H., Konrad, M., Potschger, U., Basso, G., Schrappe, M., van Dongen, J.J., Bartram, C.R., Biondi, A. & Panzer-Grumayer, E.R. High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias. *Leukemia* **18**, 84-91 (2004).
- Fine, B.M., Stanulla, M., Schrappe, M., Ho, M., Viehmann, S., Harbott, J. & Boxer, L.M. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. *Blood* **103**, 1043-1049 (2004).
- Schaeffeler, E., Stanulla, M., Greil, J., Schrappe, M., Eichelbaum, M., Zanger, U.M. & Schwab, M. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. *Leukemia* **17**, 1422-1424 (2003).
- Lauten, M., Cario, G., Asgedom, G., Welte, K. & Schrappe, M. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. *Haematologica* **88**, 1253-1258 (2003).
- Lauten, M., Beger, C., Gerdes, K., Asgedom, G., Kardinal, C., Welte, K. & Schrappe, M. Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. *Leukemia* **17**, 1551-1556 (2003).
- Lauten, M., Asgedom, G., Welte, K., Schrappe, M. & Stanulla, M. Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. *Haematologica* **88**, 353-354 (2003).
- Langer, T., Metzler, M., Reinhardt, D., Viehmann, S., Borkhardt, A., Reichel, M., Stanulla, M., Schrappe, M., Creutzig, U., Ritter, J., Leis, T., Jacobs, U., Harbott, J., Beck, J.D., Rascher, W. & Repp, R. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. *Genes Chromosomes Cancer* **36**, 393-401 (2003).
- Jumaa, H., Bossaller, L., Portugal, K., Storch, B., Lotz, M., Flemming, A., Schrappe, M., Postila, V., Riiikonen, P., Pelkonen, J., Niemeyer, C.M. & Reth, M. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. *Nature* **423**, 452-456 (2003).

- Beger, C., Gerdes, K., Lauten, M., Tissing, W.J., Fernandez-Munoz, I., Schrappe, M. & Welte, K. Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach. *Br J Haematol* **122**, 245-252 (2003).
- Wuchter, C., Ruppert, V., Schrappe, M., Dorken, B., Ludwig, W.D. & Karawajew, L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cyto-reduction in vivo in childhood T-cell acute lymphoblastic leukemia. *Blood* **99**, 4109-4115 (2002).
- Takeuchi, S., Takeuchi, N., Tsukasaki, K., Bartram, C.R., Zimmermann, M., Schrappe, M., Taguchi, H. & Koeffler, H.P. Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia. *Br J Haematol* **119**, 985-987 (2002).
- Lauten, M., Matthias, T., Stanulla, M., Beger, C., Welte, K. & Schrappe, M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. *Leukemia* **16**, 1437-1442 (2002).
- Borkhardt, A., Wuchter, C., Viehmann, S., Pils, S., Teigler-Schlegel, A., Stanulla, M., Zimmermann, M., Ludwig, W.D., Janka-Schaub, G., Schrappe, M. & Harbott, J. Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. *Leukemia* **16**, 1685-1690 (2002).
- Stanulla, M., Schrauder, A., Welte, K. & Schrappe, M. Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. *BMC Blood Disord* **1**, 2 (2001).
- Wuchter, C., Karawajew, L., Ruppert, V., Schrappe, M., Harbott, J., Ratei, R., Dorken, B. & Ludwig, W.D. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. *Br J Haematol* **110**, 154-160 (2000).
- Stanulla, M., Kasper, B., Schrappe, M., Viehmann, S., Harbott, J., Ludwig, W.D. & Welte, K. Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life. *Leukemia* **14**, 337-338 (2000).
- Anderer, G., Schrappe, M., Brechlin, A.M., Lauten, M., Muti, P., Welte, K. & Stanulla, M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. *Pharmacogenetics* **10**, 715-726 (2000).
- Dworzak, M.N., Stolz, F., Froschl, G., Printz, D., Henn, T., Fischer, S., Fleischer, C., Haas, O.A., Fritsch, G., Gadner, H. & Panzer-Grumayer, E.R. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods. *Exp Hematol* **27**, 673-681 (1999).

- Norga, K., Pless, M., Stanulla, M., TePas, E.C. & Mathey-Prevot, B. Multiple transcription start sites and 5' alternate splicing of murine IL-3 receptor beta-chain transcripts. *Biochem Biophys Res Commun* **205**, 886-892 (1994).
- Ludwig, W.D., Reiter, A., Loffler, H., Gokbuget, Hoelzer, D., Riehm, H. & Thiel, E. Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL. *Leuk Lymphoma* **13 Suppl 1**, 71-76 (1994).
- Izraeli, S., Henn, T., Strobl, H., Ludwig, W.D., Kovar, H., Haas, O.A., Harbott, J., Bartram, C.R., Gardner, H. & Lion, T. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. *Leukemia* **7**, 2054-2056 (1993).
- Izraeli, S., Kovar, H., Gardner, H. & Lion, T. Unexpected heterogeneity in E2A PBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia. *Blood* **80**, 1413-1417 (1992).
- Niemeyer, C.M., Reiter, A., Riehm, H., Donnelly, M., Gelber, R.D. & Sallan, S.E. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols. *Ann Oncol* **2**, 745-749 (1991).